{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Testing&page=15",
    "query": {
      "intervention": "Safety Testing",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 1467,
    "total_pages": 147,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Testing&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Testing&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T23:08:56.163Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05824585",
      "title": "DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "DZD8586",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dizal Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2023-05-15",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-23T23:08:56.163Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05824585"
    },
    {
      "nct_id": "NCT03641768",
      "title": "Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alzheimer Dementia",
        "Posttraumatic Stress Disorder",
        "Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "MRI",
          "type": "DEVICE"
        },
        {
          "name": "PET",
          "type": "DEVICE"
        },
        {
          "name": "18F-Florbetapir",
          "type": "DEVICE"
        },
        {
          "name": "Radioligand 18F-AV-1451",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-01-01",
      "completion_date": "2021-01-01",
      "has_results": false,
      "last_update_posted_date": "2018-10-16",
      "last_synced_at": "2026-10-23T23:08:56.163Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03641768"
    },
    {
      "nct_id": "NCT03449524",
      "title": "PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PAH"
      ],
      "interventions": [
        {
          "name": "75mg CXA-10",
          "type": "DRUG"
        },
        {
          "name": "150mg CXA-10",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Complexa, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 69,
      "start_date": "2018-08-01",
      "completion_date": "2020-08-05",
      "has_results": false,
      "last_update_posted_date": "2020-08-10",
      "last_synced_at": "2026-10-23T23:08:56.163Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03449524"
    },
    {
      "nct_id": "NCT06959524",
      "title": "AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Arterial Disease (CAD)",
        "de Novo Lesions in Native Coronary Arteries"
      ],
      "interventions": [
        {
          "name": "Drug Eluting Balloon",
          "type": "DEVICE"
        },
        {
          "name": "Drug eluting stent",
          "type": "DEVICE"
        },
        {
          "name": "Plain old balloon angioplasty",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Boston Scientific Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1616,
      "start_date": "2025-08-21",
      "completion_date": "2032-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-23T23:08:56.163Z",
      "location_count": 48,
      "location_summary": "Scottsdale, Arizona • Jonesboro, Arkansas • La Jolla, California + 40 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06959524"
    },
    {
      "nct_id": "NCT05136170",
      "title": "Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "Cenegermin",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2022-01-27",
      "completion_date": "2023-05-24",
      "has_results": true,
      "last_update_posted_date": "2025-11-26",
      "last_synced_at": "2026-10-23T23:08:56.163Z",
      "location_count": 7,
      "location_summary": "Glendale, California • Baltimore, Maryland • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Garden City",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05136170"
    },
    {
      "nct_id": "NCT02311582",
      "title": "MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malignant Glioma"
      ],
      "interventions": [
        {
          "name": "MK-3475",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MRI-guided laser ablation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2015-08-05",
      "completion_date": "2024-04-15",
      "has_results": true,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-10-23T23:08:56.163Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida • St Louis, Missouri",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02311582"
    },
    {
      "nct_id": "NCT00688688",
      "title": "Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Bladder, Overactive"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Tolterodine",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Tolterodine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2792,
      "start_date": "2008-04-25",
      "completion_date": "2010-05-06",
      "has_results": true,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-10-23T23:08:56.163Z",
      "location_count": 106,
      "location_summary": "Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00688688"
    },
    {
      "nct_id": "NCT01283425",
      "title": "Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "InsuPatch",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Insuline Medical Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 147,
      "start_date": "2011-02",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2014-09-04",
      "last_synced_at": "2026-10-23T23:08:56.163Z",
      "location_count": 1,
      "location_summary": "San Mateo, California",
      "locations": [
        {
          "city": "San Mateo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01283425"
    },
    {
      "nct_id": "NCT05662319",
      "title": "A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia"
      ],
      "interventions": [
        {
          "name": "Fitusiran",
          "type": "DRUG"
        },
        {
          "name": "Clotting factor concentrates (CFC) or bypassing agents (BPA)",
          "type": "DRUG"
        },
        {
          "name": "Antithrombin concentrate (ATIIIC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 91,
      "start_date": "2023-02-01",
      "completion_date": "2029-01-25",
      "has_results": false,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-10-23T23:08:56.163Z",
      "location_count": 8,
      "location_summary": "Orange, California • Minneapolis, Minnesota • Hackensack, New Jersey + 5 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05662319"
    },
    {
      "nct_id": "NCT01365039",
      "title": "Safety and Efficacy of a Contact Lens for Daily Disposable Use",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Myopia"
      ],
      "interventions": [
        {
          "name": "Test, daily disposable contact lens",
          "type": "DEVICE"
        },
        {
          "name": "SofLens daily disposable contact lens",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 173,
      "start_date": "2011-06",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2014-01-08",
      "last_synced_at": "2026-10-23T23:08:56.163Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01365039"
    }
  ]
}